NCT01787916View on ClinicalTrials.gov

52 Week Trial of Liraglutide in Type 1 Diabetes

PHASE4CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Type 1 Diabetes

Interventions

DRUG

Liraglutide

Liraglutide will be compared to placebo for 24 weeks in a cross-over design

DRUG

Placebos

placebo will be compared to liraglutide for 24 weeks in a cross-over design

Trial Locations (1)

G1V 4G2

CHU de Québec, Québec

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Novo Nordisk A/S

INDUSTRY

lead

CHU de Quebec-Universite Laval

OTHER

NCT01787916 - 52 Week Trial of Liraglutide in Type 1 Diabetes | Biotech Hunter | Biotech Hunter